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See Article, pages 108–117To predict the future has always been a major concern of human-
ity. To identify prognostic factors of death and survival is one
facet of this concern. A prognostic model is a combination of var-
ious factors related to survival in a given disease which allows for
the prediction of outcome. Such prognostic models can help to
determine the best route for treatment, help to inform patients
and their relatives of the prognosis, and to stratify patients in
clinical studies. An ideal classiﬁcation should use simple and eas-
ily reproducible clinical variables, clearly sort out patients into
several groups with different survival outcomes, and be usable
in all populations of patients whatever their origin and the cause
of their underlying liver disease. Is there such an ideal classiﬁca-
tion for hepatocellular carcinoma (HCC)?
HCC almost always occurs in patients with chronic liver dis-
ease, usually cirrhosis [1]. Accordingly, survival is strongly inﬂu-
enced by factors related both to tumour extension and liver
impairment as well as the occurrence of new tumours. The clas-
siﬁcations, including variables only related either to tumour bur-
den or liver function, such as Tumour Node Metastasis (TNM) and
Child-Pugh classiﬁcations, have obviously insufﬁcient perfor-
mance in patients with HCC [2,3]. From the ﬁrst popular classiﬁ-
cation proposed by Okuda et al. [4] in 1985 to more recent
models such as BCLC (Barcelona Clinic Liver Cancer) [5], GRETCH
(Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire)
[6], CLIP (Cancer of Liver Italian Program) [7], CUPI (Chinese Uni-
versity Prognostic Index) [8], and JIS (Japanese Integrated Sys-
tem) [9], all classiﬁcations combine parameters reﬂecting
tumour extension (number and size of nodules, vascular invasion,
and serum alpha-fetoprotein level) and liver impairment (serum
bilirubin, serum albumin, prothrombin activity, ascites, and
degree of portal hypertension). Some models also incorporate
variables related to patient performance status [5,6]. In this issue
of the Journal, Hsu et al. [10] propose a new prognostic model
based on total tumour volume calculated by adding up the vol-
umes of all measurable tumours visible on imaging examinations.
High total tumour volume was signiﬁcantly correlated withJournal of Hepatology 20
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parameter with Child-Pugh classiﬁcation and serum alpha-feto-
protein level.
Which is currently the best (ideal) prognostic classiﬁcation for
HCC? There is no consensual answer [11]. However, several clues
can help to clarify this topic, coming from recent changes in HCC
epidemiology and from clinical studies comparing classiﬁcations
between them. Due to its great simplicity, Okuda’s score has been
widely used for a long time, both in clinical practice and research.
However, this score has been built empirically from a population
of patients mainly with advanced HCC [4]. The variable reﬂecting
tumour burden (more or less than 50% of total liver volume) is
difﬁcult to assess precisely by imaging and is not adapted to
the increasing population of patients with small (early) HCC at
diagnosis. Recent studies have clearly indicated that Okuda’s
score has lower prognostic performance than more recent classi-
ﬁcations [6,7,12] and that its use is no longer justiﬁed. On the
other hand, several studies have found a better performance of
the BCLC staging system when compared to other recent classiﬁ-
cations [3,12,13]. In the study by Marrero et al. [12] performed in
239 patients with cirrhosis and HCC, BCLC classiﬁcation had the
best predictive power for survival when compared to six other
prognostic models (Okuda, TNM, CLIP, GRETCH, CUPI, and JIS clas-
siﬁcations). Such a performance is likely due to the fact that it
takes into account several important factors such as liver func-
tion, portal hypertension, general status, and tumour characteris-
tics with special attention focused on small tumours. The BCLC
classiﬁcation has at least two major advantages. Firstly, it is the
most widely accepted classiﬁcation and the most likely to
become the international standard: whatever classiﬁcation used,
it must utilize only one language. Secondly, it is a staging system
as well as a prognostic classiﬁcation, which helps clinicians make
more rational decisions for treatment and deﬁne proper selection
criteria for randomized and non-randomized trials. Accordingly,
recent international guidelines recommend the BCLC classiﬁca-
tion to assess prognosis and to guide decision making process
with regards to therapeutic options in patients with HCC [1].
Is this recommendation the end of the story and should we all
deﬁnitively use the BCLC classiﬁcation? Have we found the Holy
Grail of prognostic models for HCC? The reply is probably nega-
tive. As previously emphasized, epidemiological characteristics10 vol. 53 j 23–24
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and the treatment of patients with HCC have been markedly
modiﬁed and hopefully improvements are yet to come. A better
identiﬁcation of patients with chronic liver diseases and cirrhosis
would allow to include them in a periodic surveillance program
[14]. Recent studies have shown important increases in the rate
of patients with small HCC at diagnosis, up to 70% [15]. This fact
clearly accounts for currently low performance of prognostic
classiﬁcations such as Okuda’s score, established a long time
ago when patients primarily had advanced HCC at diagnosis.
Future classiﬁcations will have to identify new, more relevant
variables that discriminate between patients with small, early
HCC without any vascular or extra-hepatic extension. It is likely
that molecular tools, that allow for better characterization of
the biological properties of tumours, will be useful for reaching
this goal [16]. Moreover, we have to keep in mind that prognostic
models generally do not assess spontaneous survival. Due to the
high rate of patients with small tumours, many patients receive
curative treatment such as surgery or local ablation, [1] and in
this latter ﬁeld particularly, techniques are improving rapidly.
Therefore, the therapeutic options suggested by the BCLC staging
have to be modiﬁed accordingly in the future. Even in patients
with advanced tumours, palliative treatments such as arterial
chemoembolization [1] or sorafenib [17] are now increasingly
used in patients who were receiving only conservative treat-
ments in the past. In addition, a lot of advances have been made
in the management of patients with chronic liver diseases and
cirrhosis, such as the effective prevention and treatment of vari-
ceal haemorrhages, but also in antiviral treatment of chronic HCV
and HBV infections. These parameters are never taken into
account in prognostic studies even if they do modify the outcome
of patient survival. Finally, it seems to be clear that a deﬁnitive
universal prognostic classiﬁcation for HCC survival does not exist
(and likely will never exist). A more realistic way to approach
this, is to build speciﬁc prognostic models adapted to well-
deﬁned subsets of patients that takes into account each therapeu-
tic option. Some models developed in patients with only (or
mostly) advanced HCC [18], early-intermediate HCC undergoing
non-surgical treatment [19], or resection [20] have been recently
published. In patients with small HCC and very well compensated
liver disease, it is unlikely that the usual clinical and biological
parameters could be useful for building a prognostic model. More
sophisticated variables, based on liver histology or molecular
analysis, should be tested [16,21,22]. Such prognostic classiﬁca-
tions, speciﬁc to each precise situation, will need to be periodi-
cally revised in order to follow both future changes in
epidemiology, better knowledge of liver carcinogenesis, and
improvement of therapy.Conﬂicts of interest
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